We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
-11.22%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$192M
AUM Growth
-$269M
(-58%)
Cap. Flow
-$237M
Cap. Flow
% of AUM
-123.24%
Top 10 Holdings %
Top 10 Hldgs %
57.46%
Holding
50
New
8
Increased
10
Reduced
11
Closed
17
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$9.47M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$5.89M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$5.72M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$5.04M |
| 5 |
Axsome Therapeutics
AXSM
|
+$4.13M |
Top Sells
| 1 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$10.4M |
| 2 |
Celldex Therapeutics
CLDX
|
+$8.71M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$6.13M |
| 4 |
Cogent Biosciences
COGT
|
+$5.46M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
+$4.39M |
Sector Composition
| 1 | Healthcare | 75.76% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $29.7M | 15.47% |
+400,000
| New | +$30M |
|
|
2
CALL
Celldex Therapeutics
CLDX
$2.77B
| $10.8M | 5.62% |
+400,000
| New | +$11.6M |
|
|
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
| $10.7M | 5.59% |
1,000,000
-100,000
| -9% | -$824K |
|
|
APLS
4
DELISTED
Apellis Pharmaceuticals
APLS
| $10.2M | 5.3% |
225,000
-25,000
| -10% | -$1.14M |
|
|
5
Sarepta Therapeutics
SRPT
$1.82B
| $9.74M | 5.08% |
130,000
+80,000
| +160% | +$5.89M |
|
|
6
Axsome Therapeutics
AXSM
$11.8B
| $8.62M | 4.49% |
225,000
+130,500
| +138% | +$4.13M |
|
|
7
Cogent Biosciences
COGT
$6.68B
| $8.12M | 4.23% |
900,000
-800,000
| -47% | -$5.46M |
|
|
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $7.98M | 4.15% |
+100,000
| New | +$9.47M |
|
|
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.38M | 3.85% |
110,000
+90,000
| +450% | +$5.72M |
|
10
Vaxcyte
PCVX
$8.12B
| $7.07M | 3.68% |
325,000
+25,000
| +8% | +$579K |
|
|
11
Ascendis Pharma A/S
ASND
$17.1B
| $6.97M | 3.63% |
75,000
-65,000
| -46% | -$6.13M |
|
12
Viridian Therapeutics
VRDN
$1.99B
| $6.94M | 3.62% |
600,000
+133,597
| +29% | +$1.8M |
|
|
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
| $6.19M | 3.23% |
+35,000
| New | +$5.04M |
|
|
KRTX
14
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $5.69M | 2.97% |
45,000
-15,000
| -25% | -$1.72M |
|
|
MRUS
15
DELISTED
Merus
MRUS
| $5.66M | 2.95% |
250,000
-150,000
| -38% | -$3.13M |
|
|
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.81M | 2.51% |
500,000
+50,000
| +11% | +$628K |
|
|
CTIC
17
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $4.78M | 2.49% |
800,000
-500,000
| -38% | -$2.56M |
|
18
Relmada Therapeutics
RLMD
$550M
| $4.75M | 2.47% |
250,000
+150,000
| +150% | +$3.27M |
|
19
Arvinas
ARVN
$517M
| $4.63M | 2.41% |
110,000
| – | – |
|
20
Syndax Pharmaceuticals
SNDX
$2.02B
| $4.33M | 2.25% |
225,000
| – | – |
|
21
Design Therapeutics
DSGN
$785M
| $3.85M | 2.01% |
275,000
+75,000
| +38% | +$1.01M |
|
|
KZR
22
DELISTED
Kezar Life Sciences
KZR
| $3.72M | 1.94% |
45,000
+5,000
| +13% | +$441K |
|
|
23
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $3.71M | 1.93% |
50,000
-250,000
| -83% | -$18.8M |
|
24
BioCryst Pharmaceuticals
BCRX
$2.36B
| $3.44M | 1.79% |
325,000
-25,000
| -7% | -$258K |
|
|
RAPT
25
DELISTED
RAPT Therapeutics
RAPT
| $3.01M | 1.57% |
20,625
-10,625
| -34% | -$1.42M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q2 2022 Portfolio in Review
As of Q2 2022, Ghost Tree Capital held 50 positions worth $192M, down 58% from $461M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Ghost Tree Capital withdrew a net $237M in Q2 2022, closing 17 positions and reducing 11 holdings. Its most notable exit was Sierra Oncology, Inc. Common Stock, an estimated $10.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 43% a quarter earlier, followed by Financials.
Against the trend, Ghost Tree Capital opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $7.98M.
- Ghost Tree Capital's largest Q2 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 100,000 shares worth $7.98M.
- Ghost Tree Capital added most to Sarepta Therapeutics in Q2 2022, an estimated $5.89M increase.
- Ghost Tree Capital's biggest Q2 2022 reduction was Ascendis Pharma A/S, cutting an estimated $6.13M.
- Ghost Tree Capital fully exited Sierra Oncology, Inc. Common Stock in Q2 2022, selling an estimated $10.4M.
- Ghost Tree Capital's ten largest holdings make up 57% of its $192M portfolio in Q2 2022.
- Ghost Tree Capital opened 8 new positions and closed 17 in Q2 2022.
- Ghost Tree Capital's portfolio value fell 58% quarter-over-quarter to $192M.
Based on Ghost Tree Capital's 13F filing for Q2 2022, filed 15 Aug 2022.